 |
 |
|
|
RESÚMENES DICIEMBRE 2004 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Cognitive
functioning in schizophrenia and bipolar disorder: comparison of performance on
the Repeatable Battery for the Assessment of Neuropsychological Status
Faith Dickerson,
John J. Boronow, Cassie Stallings, Andrea E. Origoni, Sara K. Cole and Robert
H. Yolken
Psychiatry Research. Volume 129, Issue 1, 30 November
2004, Pages 45-53
Walter Deberdt,
Andrew Winokur, Patrizia A. Cavazzoni, Quynh N. Trzaskoma, Christopher D.
Carlson, Frank P. Bymaster, Karen Wiener, Michel Floris and Alan Breier
European Neuropsychopharmacology. Volume 15, Issue 1,
January 2005, Pages 13-21
Pierre Chue,
Marielle Eerdekens, Ilse Augustyns, Bernard Lachaux, Peter Molčan, Lars
Eriksson, H. Pretorius and Anthony S. David
European Neuropsychopharmacology. Volume 15, Issue 1,
January 2005, Pages 111-117
Swaran P. Singh, Tom Burns, Shazad Amin, Peter B. Jones, Glynn Harrison
The British Journal of Psychiatry (2004) 185: 452-459
Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms
Rebekka Lencer, Gunnar Eismann, Meike Kasten, Kemal Kabakci, Verena
Geithe, Jenny Grimm,
Christine Klein
The British Journal of Psychiatry (2004) 185: 465-471
Prediction of
changes in memory performance by plasma homovanillic acid levels in
clozapine-treated patients with schizophrenia
Tomiki Sumiyoshi,
A. Roy, C.-H. Kim, K. Jayathilake, M. A. Lee,
C. Sumiyoshi and H. Y. Meltzer
Psychopharmacology 2004; Volume 177, Numbers
1-2: 79 - 83
Risperidone
plasma levels, clinical response and side-effects.
Riedel M, Schwarz MJ,
Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller
HJ.
Eur Arch Psychiatry Clin Neurosci. 2004 Nov 29; [Epub
ahead of print]
A comparison of
two novel antipsychotics in first episode non-affective psychosis: one-year
outcome on symptoms, motor side effects and cognition
Ashok Malla, Ross
Norman, Derek Scholten, Laurel Townsend, Rahul Manchanda, Jatinder Takhar and
Raj Haricharan
Psychiatry Research. Volume 129, Issue 2, 15 December
2004, Pages 159-169
Tuula Ilonen, Tero
Taiminen, Hasse Karlsson, Hannu Lauerma, Kirsi-Marja Leinonen, Elina Wallenius
and Raimo K.R. Salokangas
Psychiatry Research. Volume 129, Issue 2, 15 December
2004, Pages 191-199
Michael J. Sernyak,
and Robert Rosenheck
J Clin Psychiatry 2004;65:1597-1600
Efficacy and Tolerability of Ziprasidone Versus Risperidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder: An 8-Week, Double-Blind, Multicenter Trial
Donald E. N.
Addington, Christos Pantelis, Mary Dineen, Isma Benattia, and Steven J. Romano
J Clin Psychiatry 2004;65:1624-1633
Jeffrey W. Swanson,
Marvin S. Swartz, Eric B. Elbogen, and Richard A. Van Dorn
J Clin Psychiatry 2004;65:1666-1673
Is it worth while
changing clinically stable schizophrenic out-patients with mild to moderate
residual symptoms and/or side effects from conventional to atypical
antipsychotics? A prospective, randomised study with olanzapine
Björn Appelberg,
Katinka Tuisku and Grigori Joffe
European Psychiatry. Volume 19, Issue 8, December
2004, Pages 516-518
Prefrontal atrophy
in first episodes of schizophrenia associated with limbic metabolic
hyperactivity
Vicente Molina,
Javier Sanz, Fernando Sarramea, Carlos Benito and Tomás Palomo
Journal of Psychiatric Research. Volume 39, Issue 2,
March 2005, Pages 117-127
Tools for measuring clinical
effectiveness
Dieter Naber and
Antonio Vita
European Neuropsychopharmacology. Volume 14,
Supplement 4, November 2004, Pages S435-S444
Ruth I. Ohlsen,
Mary S. O'Toole, Rick G. Purvis, James T.R. Walters, Teresa M. Taylor, Hugh M.
Jones and Lyn S. Pilowsky
European Neuropsychopharmacology. Volume 14,
Supplement 4, November 2004, Pages S445-S451
James M. Gold
Schizophrenia Research. Volume 72, Issue 1, 15
December 2004, Pages 21-28
Elena Yablonsky-Alter, Eleonora Gashi, Theodore I. Lidsky, Hoau-Yan
Wang, and Shailesh P. Banerjee
Olanzapine-induced cerebral metabolic changes related to symptom
improvement in schizophrenia.
Molina, Vicente; Gispert, Juan D; Reig,
Santiago; Pascau, Javier; Martinez, Raul; Sanz, Javier; Palomo, Tomas; Desco,
Manuel
International Clinical Psychopharmacology.
20(1):13-18, January 2005.
Antipsychotic treatment and sexual functioning in first-time
neuroleptic-treated schizophrenic patients.
Bitter, Istvan; Basson, Bruce R;
Dossenbach, Martin R
International Clinical Psychopharmacology.
20(1):19-21, January 2005.
The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced
akathisia: an open label preliminary study.
Gross-Isseroff, Ruth; Magen, Ayelet;
Shiloh, Roni; Hermesh, Haggai; Weizman, Abraham
International Clinical Psychopharmacology.
20(1):23-25, January 2005.
Negative symptoms of schizophrenia are improved by the addition of
paroxetine to neuroleptics: a double-blind placebo-controlled study.
Jockers-Scherubl, M. C; Bauer, A; Godemann,
F; Reischies, F. M; Selig, F; Schlattmann, P
International Clinical Psychopharmacology.
20(1):27-31, January 2005.
Incidence of diabetes in a general practice population: a database
cohort study on the relationship with haloperidol, olanzapine, risperidone or
quetiapine exposure.
Sacchetti, Emilio; Turrina, Cesare;
Parrinello, Giovanni; Brignoli, Ovidio; Stefanini, Giovanni; Mazzaglia,
Giampiero
International
Clinical Psychopharmacology. 20(1):33-37, January 2005.
Plasma Leptin and Adiposity During Antipsychotic Treatment of
Schizophrenia
Dan W Haupt, Angela Luber, Justin
Maeda, Angela K Melson, Julie A Schweiger and John W Newcomer
Neuropsychopharmacology (2005) 30, 184-191
Restoration of
frontal activation during a treatment with quetiapine: an fMRI study of blunted
affect in schizophrenia
Emmanuel Stip,
Cherine Fahim, Adham Mancini-Marïe, Lahcen Ait Bentaleb, Boualem Mensour,
Adrianna Mendrek and Mario Beauregard
Schizophrenia with
prominent catatonic features (‘catatonic schizophrenia’). I. Demographic and
clinical correlates in the chronic phase
Gabor S. Ungvari,
Siu Kau Leung, Fung Shing Ng, Hung-Kin Cheung and Tony Leung
Striatal
dopaminergic D2 receptor occupancy and clinical efficacy in psychosis
exacerbation: a 123I-IBZM study with ziprasidone and haloperidol
Iluminada Corripio,
Ana M. Catafau, Víctor Perez, Dolors Puigdemont, Esther Mena, Yolanda Aguilar,
Ignasi Carrió and Enric Álvarez
Linda S. Godleski,
L. Jane Goldsmith, W. Victor R. Vieweg, Nancy Zettwoch, Dejzi Stikovac and
Susan Lewis
Systematic review
of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a
meta-analysis of randomized controlled trials
Irina A. Tammenmaa,
Eila Sailas, John J. McGrath, Karla Soares-Weiser and Kristian Wahlbeck
Yong-Ku Kim, Aye-Mu
Myint, Bun-Hee Lee, Chang-Su Han, Heon-Jeong Lee, Dae-Jin Kim and Brian E.
Leonard
The cognitive
neuropsychiatry of delusions: from psychopathology to neuropsychology and back
again
JAMES GILLEEN
and ANTHONY S. DAVID
Psychological Medicine (2005), 35:1:5-12
A. BARRERA,
P. J. McKENNA and G. E. BERRIOS
Psychological Medicine (2005), 35:1:121-132
Pharmacokinetics
of aripiprazole and concomitant lithium and valproate.
Citrome L, Josiassen R,
Bark N, Salazar DE, Mallikaarjun S
J Clin Pharmacol. 2005 Jan;45(1):89-93
Effect
of erythromycin on metabolism of quetiapine in Chinese suffering from
schizophrenia.
Li KY, Li X, Cheng ZN,
Zhang BK, Peng WX, Li HD.
Eur J Clin Pharmacol. 2004 Dec 14; [Epub ahead of
print]
Measurement and
Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS
initiative to support the development of agents for improving cognition in
schizophrenia
Stephen R. Marder
and Wayne Fenton
Schizophrenia Research. Volume 72, Issue 1, 15 December 2004, Pages 5-9
.